HLA-DRB1 and myeloid sarcoma: Results showed statistically significant additive interactions between HLA‐E*01:01 and IM diagnosis in increasing MS risk for any given combination of HLA‐DRB1*15:01 and HLA‐A*02:01 alleles (p < 0.001), with an estimated AP ≈ 40% in HLA‐E*01:01 heterozygotes and ≈ 65% in HLA‐E*01:01 homozygotes (see Supporting Information for further details).